Molecular alterations in oral cancer between tobacco chewers and smokers using serum proteomics

Abstract

BACKGROUND:

Tobacco exposure (through smoking or chewing) is one of the predominant risk factors associated with the development of oral squamous cell carcinoma (OSCC). Despite the growing number of patients diagnosed with OSCC, there are few circulating biomarkers for identifying individuals at a higher risk of developing the disease. Successful identification of candidate molecular markers for risk assessment could aid in the early detection of oral lesions and potentially be used for community screening of high-risk populations.

OBJECTIVE:

Identification of differentially expressed proteins in the serum of oral cancer patients which can serve as biomarkers for the diagnosis of the onset of oral cancer among tobacco users.

METHODS:

We employed a tandem mass tag (TMT)-based quantitative proteomics approach to study alterations in the serum proteomes of OSCC patients based on their tobacco exposure habits (chewing and smoking) compared to healthy individuals with no history of using any form of tobacco or any symptoms of the disease.

RESULTS:

Mass spectrometry-based analysis resulted in the identification of distinct signatures in the serum of OSCC patients who either chewed or smoked tobacco. Pathway analysis revealed opposing effects of dysregulated proteins enriched in the complement-coagulation signaling cascades with a high expression of the Serpin family of proteins observed in OSCC patients who chewed tobacco compared to healthy individuals whereas these proteins showed decreased levels in OSCC patients who smoked. ELISA-based validation further confirmed our findings revealing higher expression of SERPINA6 and SERPINF1 across serum of OSCC patients who chewed tobacco compared to healthy individuals.

CONCLUSIONS

: This study serves as a benchmark for the identification of serum-based protein markers that may aid in the identification of high-risk patients who either chew tobacco or smoke tobacco.

Keywords

Oral cancer squamous cell carcinoma tobacco mass spectrometry serum proteomics cigarette smoke

Abbreviations

BCA	Bicinchoninic acid assay
ELISA	Enzyme-Linked Immunosorbent
	Assay
HPLC	High-Performance Liquid
	Chromatography
LC-MS/MS	Liquid chromatography-mass
	spectrometry
OSCC	Oral Squamous Cell Carcinoma
PAGE	Polyacrylamide Gel
	Electrophoresis
ROC	Receiver operating characteristic
SCX	Strong cation exchange
SDS	Sodium Dodecyl Sulfate
SERPINs	Serine proteinase inhibitors
TEABC	Triethyl ammonium bicarbonate
TMT	Tandem Mass Tags

1. Introduction

Tobacco is predominantly consumed in its smoking form (cigarettes, smoking of ‘bidis,’ or cigars) worldwide and is one of the leading causes of oral cancer [1, 2]. Studies have reported the molecular alterations due to cigarette smoke and its constituents in oral and esophageal cancers [3, 4, 5]. However, in certain South-East Asian countries, another form of tobacco consumption that is widely popular is the chewing tobacco [6]. Numerous studies have reported the use of multiple forms of smokeless tobacco, including chewing tobacco, as a significant risk factor and/or cause for oral squamous cell carcinoma (OSCC) cases [7, 8, 9]. Studies also indicate the increased risk of oral cancer due to chewing tobacco compared to those with no habits of consuming tobacco [10, 11]. We and others have shown that both chewing and smoking tobacco’s adverse effects lead to alteration of multiple metabolic functions/pathways [12, 13]. Our group has previously reported signature molecular alterations in normal oral keratinocytes chronically subjected to cigarette smoke and chewing tobacco [14]. Thus, despite the mode of tobacco intake, its use in any form, smoking or smokeless, is implicated in the development of multiple cancers, including OSCC [15].

Though numerous epidemiological studies have demonstrated the correlation of smoking and chewing tobacco with oral cancers [7, 16], very few have focused on the difference in the effects of cigarette smoke and chewing tobacco at the molecular level. As the constituents between the two forms of tobacco vary significantly [17, 18, 19], it is evident that the mode of action among these two tobacco products also varies considerably. Thus, it is important to understand and differentiate the molecular changes induced by smoking and chewing tobacco, even when it comes to the early detection or screening of the population for risk assessment. Multiple groups have used body fluids such as serum and saliva to identify clinical biomarkers for OSCC [20, 21, 22]. Several serum biomarkers such as adiponectin, cyclin D1, C-Reactive Protein (CRP), growth-differentiation factor (GDF 15), cytokines such as interleukin 1 beta (IL-1 $\beta$ ), interleukin 6 (IL-6), and tumor necrosis factor-alpha (TNF- $\alpha$ ) have been identified and are under investigation for their potential diagnostic or prognostic use in OSCC [23]. Liu et al. have reported cytokeratin fraction 21–1 (CYFRA 21–1) as a prognostic marker for OSCC and other malignancies [24]. Though several serum-based biomarker studies for OSCC have been reported, currently there is a lack of literature describing putative biomarkers based on the tobacco usage habits of OSCC patients.

In this study, we employed a quantitative proteomics approach to identify differentially expressed proteins in the serum from OSCC patients based on their tobacco using habits (chewing and smoking) compared to healthy volunteers with no habits and no symptoms of disease or any predisposed medical condition.

2. Materials and methods

2.1 Study subject, sample collection, and storage

Patient and control blood samples were collected after approval from the Institutional and Ethical Review Board at Dr. R. Ahmed Dental College and Hospital, Kolkata, West Bengal, and Yenepoya Medical College, Mangalore, India (YEC-1/2017/166). Informed consent was obtained from all patients and volunteers before the blood samples were collected. Only those patients diagnosed with OSCC with tobacco chewing and smoking habits were included in the study. Patients with mixed habits, any other systemic illness, or who had undergone prior surgery were excluded from the study. Blood samples were collected from healthy volunteers with no tobacco using habits, no symptoms of the disease, and no pre-existing/existing health conditions/systemic illness.

For serum isolation, blood samples were collected in BD Vacutainer Plus plastic serum tubes, kept at room temperature to coagulate for 20–30 min, followed by centrifugation at 3,000 g for 20 min at 4 ${}^{\circ}$ C. The serum samples were aliquoted and stored at $-$ 80 ${}^{\circ}$ C until further use. Haemolysed samples were not included for mass spectrometry analysis.

2.2 Sample preparation for MS analysis

LC-MS/MS approach was employed using isotopomer labels, “tandem mass tags” (TMTs), to determine the relative quantification of proteins in the serum [25]. The serum samples ( $n=$ 15, 5 for each group) from all three groups were depleted of top fourteen abundant human proteins using the Human 14 Multiple Affinity Removal System (MARS) column (Agilent Technologies, Santa Clara, CA, USA) as per the manufacturer’s instructions. Total protein amount was estimated in the samples post-depletion using the Bicinchoninic acid assay (BCA) kit (Thermo Scientific Pierce, Rockford, IL, USA). Protein amounts were normalized and confirmed using 10% SDS PAGE(Supplementary Fig. 1).

2.3 In-solution digestion and TMT labeling

Post-depletion, an equal amount of protein from the three cohorts were processed for TMT labeling. Briefly, 150 $\mu$ g protein from each sample were subjected to reduction by incubating in 40 mM Dithiothreitol (DTT) at 60 ${}^{\circ}$ C for 1 hour. Samples were further alkylated with 20 mM Iodoacetamide (IAA) at room temperature for 20 minutes in the dark. The reduced and alkylated samples were digested with trypsin (Promega, Cat # V5111) at 37 ${}^{\circ}$ C overnight. Digested samples were cleaned using C18 StageTips packed with multiple 3M Empore C18 disks, as per the protocol adapted from Rappsilber et al. [26]. Briefly, 200 $\mu$ L tips were packed with Empore C18 material. Based on our protein amount, we pressed extra cores of C18 under pressure from an air-filled plastic syringe for extra loading capacity. Conditioning of the disks was carried out, using 100% Acetonitrile (ACN), and the flow-through was discarded. The column was equilibrated by adding 30 $\mu$ L of solvent A (0.1% formic acid) and allowed to pass through the tip. This step was repeated twice and the flow-through was discarded. Meanwhile, the sample was reconstituted in 30 $\mu$ L of solvent A. Further, the re-suspended sample was loaded onto the C18 StageTips, and the flow-through was collected and re-loaded again. The column was again washed using 30 $\mu$ L of solvent A twice. The bound peptides were eluted using 30 $\mu$ L of solvent B (40% ACN, 0.1% formic acid) twice. The eluted peptides were vacuum dried using SpeedVac.

Vacuum-dried peptides were labeled with TMT (Thermo Fisher Scientific) as per manufacturer’s protocol. Two sets of 10-plex TMT experiments were carried out. The control serum sample set used for both the experiments were identical (processed and labeled together). Following TMT labeling, samples were subjected to a StageTip-based strong cation exchange (SCX)-based fractionation adapted from Kulak et al. [27]. Briefly, StageTips are prepared by stacking 5 layers of SCX sorbent in a 200 $\mu$ L pipette tip. The SCX sorbent was activated by using 100 $\mu$ L ACN (100%) and the flow-through was discarded. This was followed by equilibration of the SCX disks by passing 60 $\mu$ L 2% TFA twice. The sample reconstituted in 2% TFA was loaded on to the StageTip column and the flow-through was collected and re-loaded. This was followed by a washing step which was repeated twice by using 100 $\mu$ l 0.2% (v/v) TFA. Further, 60 $\mu$ L of the SCX fractionation buffers- SCX1 (50 mM Ammonium Acetate (AA), 20% Acetonitrile (ACN), 0.5% Formic acid(FA)), SCX2 (75 mM AA, 20% ACN, 0.5% FA), SCX3 (125 mM AA, 20% ACN, 0.5% FA), SCX4 (200 mM AA, 20% ACN, 0.5% FA), SCX5 (300 mM AA, 20% ACN, 0.5% FA) and Buffer X (5% Ammonium hydroxide, 80% ACN) were added sequentially in the order mentioned above and peptides were eluted every time in separate tubes. The eluates were vacuum-dried using a SpeedVac centrifuge and stored at $-$ 20 ${}^{\circ}$ C until LC-MS/MS analysis

2.4 Mass spectrometry analysis

The Orbitrap Fusion Tribrid mass spectrometer (Thermo Fisher Scientific, Bremen, Germany) interfaced with EASY-nLC 1200 system (Thermo Fisher Scientific) was used for the analysis of TMT-labelled samples. The MS parameters used for analysis were followed as described previously [28]. Briefly, peptides from each fraction were resuspended in 0.1% formic acid (Solvent A) and loaded onto C18 trap column (75 um $\times$ 2 cm, nanoViper, 3 $\mu$ m, 100 Å, Thermo Scientific) at a flow rate of 6 $\mu$ l/min. The peptides were resolved on a EASY-Spray C18 analytical column (EASY-Spray RSLC C18 2 $\mu$ m 15 $\times$ 50 $\mu$ m, 75 $\mu$ m, Thermo Fisher Scientific) set at 40 ${}^{\circ}$ C. The LC settings were as follows: a binary solvent system (solvent A 0.1% formic acid and solvent B: 0.1% formic acid in 80% acetonitrile) set at a flow rate set at 300 nl/min and a 120 minute gradient consisting of 5–35% solvent B for 105 minutes, 100% solvent B for 2 minutes and 100% solvent B for 13 minutes. Data were acquired in positive ion mode with data-dependent acquisition. MS1 survey scans were collected in the profile mode in the Orbitrap mass analyzer at a resolution of 120,000 at m/z 200 and a scan range of 400–1,600 m/z with a maximum injection time of 50 ms. The fragmented ions were detected using Orbitrap mass analyzer at a resolution of 60,000 at 200 m/z with a maximum injection time of 200 ms. In each duty cycle, ten most intense peaks were selected for MS/MS fragmentation using higher-energy collision dissociation (HCD) mode at 34% normalized collision energy. The isolation window was set to 2 Da. Internal calibration was performed by enabling the lock mass option using m/z 445.1200025 from ambient air [29].

2.5 Bioinformatics and statistical analysis

Proteome Discoverer 2.2 (Thermo Scientific, Bremen, Germany) was used to carry out protein identification and quantitation. All raw files were searched against Human RefSeq 92 protein database supplemented with common contaminants using SequestHT and Mascot (version 2.5.1, Matrix Science, London, UK) search algorithms. The search parameters included trypsin as the proteolytic enzyme with a maximum allowed missed cleavages of two; oxidation of methionine and acetylation of protein N-terminus was set as dynamic modifications, while static modifications included cysteine carbamidomethylation and TMT modification at N-terminus of the peptide and lysine. Precursor mass tolerance was set to 10 ppm, and fragment mass tolerance was set to 0.05 Da; all the PSMs were identified with 1% FDR. The differential expression ratios between OSCC patients with chewing and smoking habits and control samples were calculated. Proteins with differential expression ratios $\geqslant$ 1.5 or $\leqslant$ 0.66 were considered as differentially expressed. The differences across the groups were calculated using Student’s $t$ -test (two-tailed), and a $p$ -value $\leqslant$ 0.05 was considered statistically significant.

A network analysis exploring relationships between SERPINs F1 and A6 and the Complement and Coagulation cascade pathway was carried out using STRINGdb in Cytoscape 3.8.0. The gene set for the pathway was obtained from the Molecular Signatures Database (MSigDB, https://www.gsea-msigdb.org/gsea/msigdb).

2.6 Enzyme-linked immunosorbent assay (ELISA)

ELISA-based validation was carried out using serum samples from a total of 48 individuals (24 healthy individuals $+$ 24 OSCC patients with tobacco chewing habits). Validation studies could not be performed using serum samples from OSCC patients with smoking habits due to the limited sample size. ELISA plates for SERPINA6/Cortisol Binding Globulin (Novus Biologicals, Cat #NBP2-75053), and SERPINF1 (Novus Biologicals, Cat #NBP2-69889) were used. ELISA-based validation of these proteins was carried out as per the manufacturer’s instructions. A 4 Parameter Logistic (4PL) nonlinear regression model curve fit was applied where R2 $>$ 0.95 was acceptable. All experiments were done in duplicate. Statistical significance was determined using the Student’s $t$ -test, which was carried out using GraphPad Prism (version 5.0, GraphPad Software, Inc.), considering a $p$ -value of $\leqslant$ 0.05 as statistically significant. Besides, the candidate protein was evaluated for its capacity to distinguish between normal and OSCC using receiver operating characteristic (ROC) curves based on the ELISA scores, which were calculated and plotted using GraphPad Prism.

2.7 Data availability

The raw data files and the MSF files were submitted to the PRIDE partner repository [30] with dataset identifier PXD019014.

Figure 1.

Proteomics data overlap between the two study groups. A schematic representing the results of the proteomics analysis of serum samples from OSCC patients who chewed or smoked tobacco.

3. Results

3.1 Comparative proteomic analysis of serum from OSCC patients

A total of 15 serum samples, five each from healthy individuals and 10 OSCC patients with tobacco exposure (chewing $n=$ 5 and smoking $n=$ 5) were used in the discovery phase of this study. The study design employed is shown in Supplementary Fig. 2.

Table 1
A list of top six differentially expressed proteins based on tobacco using habits of OSCC patients

Protein	Description	Fold change ( $p\leqslant$ 0.05)		Functions
		Chewers v/s normal	Smokers v/s normal
ITIH1	Inter-alpha-trypsin inhibitor heavy chain H1	3.55	0.41	Calcium ion binding and serine-type endopeptidase inhibitor activity
SERPIND1	Serpin family D member 1	3.32	0.48	Serum glycoprotein and promote invasion and metastasis of cancer cells
SERPINA4	Serpin family A member 4	3.00	0.53	Play roles in many processes such as including inflammation, angiogenesis, and tumor growth
SERPINA6	Serpin family A member 6	2.91	0.60	Protease inhibitor
ITIH2	Inter-alpha-trypsin inhibitor heavy chain H2	2.89	0.48	Calcium ion binding and heparin-binding activity
GSN	Gelsolin	2.79	0.47	Involved in cellular motility and play a regulatory role during development

Figure 2.

Differential expression of serum proteins in OSCC patients. Volcano plots of the significantly differentially expressed proteins in the serum of (A) OSCC patients who chewed tobacco and healthy individuals; (B) OSCC patients who smoked and healthy individuals. The red and green dots represent significantly dysregulated proteins ( $p$ -value $\leqslant$ 0.05); (C) Venn diagram showing the distribution of differential expressed proteins (up- and down-regulated) among the two study groups.

TMT-based quantitative proteomic analysis of the OSCC serum samples categorised based on tobacco usage resulted in the identification of 760 proteins, of which 562 were quantified across at least two replicates in the tobacco-chewing set. Similarly, in the smoking set, 442 proteins were identified, of which 343 proteins were quantified across at least two replicates. A complete list of the proteins and peptides identified in the study are provided in Supplementary Tables 1–4.

The results from these two sets were compared and illustrated using a Venn diagram (Venny 2.1) to identify the number of common and differentially expressed proteins. Following the schema, as shown in Fig. 1, a comparison of identified proteins across the two groups of tobacco users, revealed 254 proteins identified exclusively in OSCC patients who chewed tobacco, whereas 35 were exclusive to OSCC patients who smoked. A total of 308 proteins were shared between the sets (Fig. 1, Supplementary Table 5). Of the 562 proteins quantified in OSCC patients who chewed tobacco, 93 were significantly dysregulated (85 upregulated and 8 downregulated; 1.5-fold cut-off, $p$ -value $\leqslant$ 0.05). Of the 343 proteins quantified in OSCC patients with smoking habits, 77 were significantly dysregulated (41 upregulated and 36 downregulated; cut off 1.5-fold cut-off, $p$ -value $\leqslant$ 0.05). These included proteins involved in platelet degranulation, including haptoglobin (HP), fibronectin (FN1), and alpha-1-acid glycoprotein 1 (ORM1). The dysregulated proteins are graphically represented as volcano plots for OSCC patients who chewed tobacco (Fig. 2A) and OSCC patients who smoked (Fig. 2B). Next, we expanded our analysis by cross-comparing the dysregulated proteins across both tobacco chewing and smoking sets (Fig. 2C, Supplementary Table 6). A comparison of the proteins significantly downregulated between the two groups (8 in chewers and 36 in smokers) revealed only one common protein, TAZ (Tafazzin). Similarly, a comparison of the significantly upregulated proteins between the two groups (85 in chewers and 41 in smokers) led to the identification of five common proteins (CD5 molecule like (CD5L); complement factor H related 2 (CFHR2); lipoprotein (LPA); lysozyme (LYZ); and apolipoprotein A2 (APOA2)). All five proteins were significantly upregulated in OSCC patients, irrespective of the form of tobacco used. We observed downregulation of ORM2 in the serum of OSCC patients who chewed tobacco and overexpression in the patients who smoked, compared to healthy individuals. Of the 85 proteins upregulated in OSCC patients who chewed tobacco, 17 proteins showed opposite trends in the serum of OSCC patients who smoked. These include such as inter-alpha-trypsin inhibitors (ITIH2, ITIH1); members of serpin gene superfamily (SERPIND1, SERPINA6, SERPINF1, SERPINF2, SERPINA4); carboxypeptidase B2 (CPB2), carboxypeptidase N catalytic chain (CPN1), coagulation factor XIII (F13A1), actin (ACTB), complement proteins (C5, C8A), apolipoprotein B (APOB), fibronectin (FN1), sex hormone-binding globulin (SHBG) and gelsolin (GSN). Table 1 provides a list of the top six proteins, which showed an inverse expression pattern based on tobacco using habits of OSCC patients.

Figure 3.

Role of the Complement and coagulation cascades pathway in OSCC. The complement and coagulation signaling cascade pathways were found to be enriched based on proteins dysregulated in OSCC patients who smoked and chewed as compared to healthy individuals. The proteins highlighted in grey were not identified in our study.

3.2 Opposing effects on complement and coagulation cascade pathways in OSCC patients based on tobacco use leading to oncogenicity

To obtain more insights and to interpret the molecular differences in the serum of OSCC patients as a result of chewing and smoking habits, we studied the respective signaling cascades using DAVID 6.8 [31]. Analysis of the dysregulated proteins from the serum of OSCC patients who chewed or smoked reflected enrichment of 5 pathways, listed in Supplementary Table 7. Interestingly, our analyses demonstrated that different modes of tobacco use exert the opposite effect on the complement and coagulation signaling cascades in OSCC patients (Fig. 3).

Our data showed contrasting expression trends of SERPIN family members in OSCC patients based on the form of tobacco used, indicating a relationship between dysregulation of SERPIN family proteins with tobacco-induced oncogenicity (Fig. 3). While increased expression levels of SERPINA4, SERPINA6, SERPIND1, SERPINF1, and SERPINF2 were observed in the serum of OSCC patients who chewed tobacco, these proteins showed decreased levels in OSCC patients who smoked. Other members, including SERPINA3 and SERPING1, were exclusively increased in OSCC patients who chewed tobacco while SERPINA5 was exclusively decreased in OSCC patients who smoked.

Figure 4.

Differential expression of SERPIN family members and their opposing trends of expression between tobacco chewing and smoking OSCC patients. Representative MS/MS spectra and its corresponding scatter plot representation for identified peptides of (A) SERPINA6, and (B) SERPINF1 in OSCC patients who chewed tobacco as compared to healthy individuals; and (C) SERPINA6, and (D) SERPINF1 in OSCC patients who smoked as compared to healthy individuals, respectively. The data presented as vertical scatter plots consisted of patient ( $n=$ 5) data represented in triplicates.

Figure 5.

Validation of SERPINA6 and SERPINF1 by ELISA. ELISA-based validation: Expression of (A) SERPINA6 and (B) SERPINF1 in OSCC patients who chewed tobacco compared to healthy controls; Receiver operating characteristic (ROC) curves for (C) SERPINA6 and (D) SERPINF1, respectively. SERPINA6: Serpin family A member 6 or Corticosteroid-Binding Globulin; SERPINF1: Serpin family F member 1. ( ${}^{****}$ , $p<$ 0.0001; and ${}^{**}$ , $p=$ 0.0067).

3.3 Validation of SERPINA6 and SERPINF1 by ELISA

The previous section showed the serpin family to be enriched and showed the opposite expression trend in mass spectrometry data (Fig. 4, Supplementary Fig. 3). We found $>$ 2-fold increased expression ( $p\leqslant$ 0.05) of both SERPINA6 (Fig. 4A) and SERPINF1 (Fig. 4B) across the OSCC patients who chewed tobacco compared to healthy individuals. On the contrary, we observed decreased expression ( $\leqslant$ 0.66-fold, $p\leqslant$ 0.05) of both SERPINA6 (Fig. 4C) and SERPINF1 (Fig. 4D) in OSCC patients who smoked. To explore the relationship of these molecules with the complement and coagulation cascade pathway, we carried out a network analysis between the dysregulated proteins identified across both sets and complement and coagulation regulatory network and observed the differences between chewers and smokers (Supplementary Fig. 4A and B). These results indicate SERPINA6 and SERPINF1 have close relationships with proteins of the complement and coagulation cascade. Further studies are warranted to explore these relationships.

We validated the expression of SERPINA6 and SERPINF1 by complementary ELISA-based approach using serum from 24 healthy controls and 24 OSCC patients who chewed tobacco (Supplementary Table 8). The levels of both the serpins were significantly higher in serum of OSCC patients who chewed tobacco compared to healthy controls (Fig. 5A and B) in agreement with our mass spectrometry findings.

A ROC curve analysis was carried out where we found the area under the ROC curve for SERPINA6 to be 0.9444 (95% CI: 0.8873–1.00223, $p$ -value $<$ 0.0001) (Fig. 5C). Similarly, ELISA-based validation revealed elevated expression of SERPINF1 in OSCC patients with chewing habits compared to healthy volunteers with an AUC of 0.8021 (95% CI: 0.6662–0.9380, $p$ -value $=$ 0.0003) (Fig. 5D).

4. Discussion

Our mass spectrometry data has generated information for candidate markers and pathways dysregulated in OSCC patients with tobacco chewing and smoking habits. The pathobiology of OSCC resulting from tobacco use, either in chewing or smoking form, differs significantly owing to the difference in composition [17, 18, 19]. We observed dysregulation of proteins associated with plasminogen signaling cascade in the serum of patients who chewed tobacco. Aberrant expression of proteins participating in such pathways includes plasminogen (PLG), fibrinogens (FGA, FGB, FGG), actin (ACTB) contributing to malignant cell cycle progression in various cancers [32, 33]. Whereas in patients who smoked, majority of the proteins dysregulated are known to be involved in the process of platelet degranulation. These proteins have previously been reported to be dysregulated in lung cancer and reported to be involved in smoking-induced epithelial disorders [34, 35].

Comparison of the significantly upregulated proteins between the two groups led to the identification of 5 common proteins which were significantly upregulated in OSCC patients, irrespective of the form of tobacco used. These included CD5 molecule like (CD5L); complement factor H related 2 (CFHR2); lipoprotein (LPA); lysozyme (LYZ); and apolipoprotein A2 (APOA2). Studies have demonstrated that altered expression of LYZ results in tumor growth and metastasis and is associated with poor prognosis in cancer patients [36, 37]. APOA2 is an essential component of high-density lipoprotein and its differential expression has been reported in various types of cancers [38]. Its increased expression has been observed in the serum of patients with prostate cancer [39] and hepatocellular carcinoma [40]; however, its decreased level was reported in pancreatic cancer [41]. A recent study by Chu et al. reported increased levels of APOA2 in the saliva of OSCC patients compared to healthy individuals [42]. Interestingly, we identified an opposite trend in serum levels of ORM2 in OSCC patients, which is a secretory plasma protein and known to be associated with inflammation and multiple cancers [43, 44, 45]. Of the 17 proteins which showed the opposite trend between OSCC patients who chewed tobacco or smoked (i.e upregulated in patients who chewed tobacco and downregulated who smoked), significant enrichment of the members of the serpin family of proteins amongst others were observed. These proteins are mainly associated with metabolic processes and have catalytic activity, and have the potential to serve as distinct signatures to distinguish between the two cohorts based on habits.

Our data revealed opposite effects on the complement and coagulation signaling cascades between patients who chewed tobacco and patients who smoked tobacco. This signaling cascade is one of the significant proteolytic pathways, consisting of serine proteinases with trypsin-like activity and their activators and inhibitors, that protect against infections [46]. The complement pathway constitutes an integral component of humoral immunity, and a coagulation system is critical in hemostasis, and their roles have been implicated in multiple diseases, including cancer [47]. Our data indicate the presence of several hub proteins regulating this pathway, such as components of fibrinogen (FGA, FGB, FGG), plasminogen (PLG), complement factors (C2, C5, C7, C9, C8A, C8G, CPB), coagulation factors (F2, F7, F13A1) along with members of serpins family (SERPIND1, SERPING1) in the serum of OSCC patients who chewed tobacco. Our analysis further indicates a high fibrinogen level in OSCC patients who chewed tobacco, promoting platelet activation (FGA, FGB, FGG), which is in accordance with our pathway analysis. Higher plasma fibrinogen is known to be associated with multiple malignancies such as colon [48], pancreatic [49], nasopharyngeal [50], and oral cancer [51]. Complement factors and serpin family members were found to be upregulated in the OSCC chewer cohort. Both serpin family G member 1 (SERPING1) and serpin family D member 1 (SERPIND1) are known to play a crucial role in the regulation of the complement cascade and studies have revealed elevated levels in the saliva of OSCC patients [52].

In the case of OSCC patients who smoked, we observed decreased expression of complement component 5 (C5), which is a part of the complement cascade known to trigger acute inflammatory responses. Recent studies have reported downstream targets of C5a to induce chronic inflammation during tissue damage, thus promoting tumor growth by recruiting myeloid-derived suppressor cells [53, 54]. Our data also showed decreased expression of several proteins downstream of this pathway, such as C8A, CPB2, and F13A1, in the serum of OSCC patients who smoked. F13A, a key regulator of the coagulation cascade and plays an important role in promoting tumorigenesis and is reported to be downregulated in the serum of colorectal cancer patients [55]. In contrast, these were found to be increased in the serum of OSCC patients who chewed tobacco.

OSCC progression is a multi-step process marked by uncontrolled cell growth, invasion, and migration [56]. Such cellular processes are controlled by proteolytic enzymes such as serine and cysteine proteases, and serine proteases are controlled by members of the SERPIN (serine protease inhibitor) family. Our findings suggest that serine protease inhibitors identified in the study can activate the complement pathway in OSCC patients. Although the role of serpins in cancer is not well established, and the underlying mechanism is not well understood, our data indicates serpins play an essential role in the pathobiology of oral cancer. Our data indicated upregulation of SERPINA6 and SERPINF1 in patients who chewed tobacco whereas these proteins were downregulated in patients who smoked. ELISA-based validation further confirmed overexpression of SERPINA6 and SERPINF1 in the serum of OSCC patients who chewed tobacco. SERPINA6 is a 52 kDa secreted $\alpha$ 1-glycoprotein that serves as a plasma transport protein for glucocorticoids and progestins. Its increased expression has been well documented in the saliva of OSCC patients [52]. SERPINF1 (also called PEDF), a 50 kDa glycoprotein, is known to inhibit angiogenesis and metastasis and induce apoptosis [57]. It acts as a ligand for many receptors and is known to inhibit VEGF-driven angiogenesis along with a decrease in ATP production via binding to laminin receptor and F1 ATP synthase, resulting in apoptosis in endothelial cells [57]. Besides, it also plays a role in inflammation and is involved in metabolic processes [58]. Martinez-Marin et al. have reported its increased expression in prostate cancer patients’ serum and its role as a therapeutic target [59].

These results suggest the possible role of SERPINA6 and SERPINF1 as potential biomarkers for OSCC patients with tobacco chewing habits. Further studies are warranted to define the functional role of these proteins in OSCC progression.

5. Conclusions

In our study, we investigated the underlying molecular alterations in OSCC based on the mode of tobacco intake. The use of tobacco, in both smoke and smokeless form, has been associated with an increased incidence of inflammation and activate complement and coagulation cascade [60, 61, 62]. We observed the dysregulation of coagulation and complement-related proteins in OSCC patients, suggesting its role in the pathogenic process of oncogenicity. However, this signaling cascade showed opposing effects owing to the different modes of tobacco intake. Our findings suggest that an imbalance of this signaling cascade contributes to the molecular basis for tumorigenic phenotype owing to tobacco use in either form. We demonstrate the promising role of SERPINA6 and SERPINF1 as potential early detection biomarkers for OSCC patients who chewed tobacco that should be tested in larger cohorts. However, we were unable to validate the same in the serum of OSCC patients who smoked due to the limited number of samples in the smoking cohort. Also, due to lack of samples, we were unable to study the expression of these proteins in subjects with a chewing or smoking tobacco habit but no oral lesion or symptoms of the disease or subjects with pre-cancerous lesions. We also did not have enough samples to explore if there was an association between the detected proteins in serum and the amount of tobacco exposure of individual patients. The study did not include patients with mixed habits (those who chewed and smoked tobacco), nevertheless, it might be interesting to extend this study by including such a cohort of patients. This work highlights the potential of serum proteins, which can serve as biomarkers to identify high-risk patients who either chew or smoke tobacco products. Further studies with larger cohorts and associated control groups are required in a clinical setting before these molecules can be taken forward as a potential risk assessment panel in OSCC patients who are tobacco users.

Author contributions

Conception: Aditi Chatterjee, T.S. Keshava Prasad, Harsha Gowda, David Sidransky

Interpretation or analysis of data: Varshasnata Mohanty, Yashwanth Subbannayya, Riaz Abdulla, Jay Gopal Ray, Shankargouda Patil, Mandakulutur S. Ganesh, Arnab Pal

Preparation of the manuscript: Varshasnata Mohanty, Yashwanth Subbannayya, Aditi Chatterjee

Revision for important intellectual content: Varshasnata Mohanty, Yashwanth Subbannayya, Aditi Chatterjee, Harsha Gowda, David Sidransky

Supervision: Aditi Chatterjee, T.S. Keshava Prasad, Harsha Gowda, David Sidransky

Supplementary data

The supplementary files are available to download from https://dx-doi-org.web.bisu.edu.cn/10.3233/CBM-203077.

sj-pdf-1-cbm-10.3233_CBM-203077.pdf - Supplemental material

Supplemental material, sj-pdf-1-cbm-10.3233_CBM-203077.pdf

sj-docx-1-cbm-10.3233_CBM-203077.docx - Supplemental material

Supplemental material, sj-docx-1-cbm-10.3233_CBM-203077.docx

Footnotes

Acknowledgments

We thank Karnataka Biotechnology and Information Technology Services (KBITS), the Government of Karnataka, for the support to the Center for Systems Biology and Molecular Medicine at Yenepoya (Deemed to be University) under the Biotechnology Skill Enhancement Programme in Multiomics Technology (BiSEP GO ITD 02 MDA 2017). We thank Yenepoya (Deemed to be University) for access to instrumentation. The first author is a recipient of the Women Scientist-A award from the Department of Science and Technology (DST), Government of India. This work was supported by the Department of Science and Technology (DST), Government of India (SR/WOS-A/LS-32/2018). We thank Dr. Sneha M. Pinto, Centre of Molecular Inflammation Research (CEMIR), Norwegian University of Science and Technology, Norway for critical reading of the manuscript, inputs to data analysis and editing.

Conflict of interest

The authors declare that they have no conflict of interest.

References

Mohtasham

Ayatollahi

Saghravanian

Zare

Shakeri

M.T.

Sahebkar

and Mohajertehran

, Evaluation of tissue and serum expression levels of lactate dehydrogenase isoenzymes in patients with head and neck squamous cell carcinoma, Anticancer Agents Med Chem 19 (2019), 2072–2078.

Rajagopalan

Nanjappa

Raja

Jain

A.P.

Mangalaparthi

K.K.

Sathe

G.J.

Babu

Patel

Cavusoglu

Soeur

Pandey

Roy

Breton

Chatterjee

Misra

and Gowda

, How does chronic cigarette smoke exposure affect human skin? A global proteomics study in primary human keratinocytes, OMICS 20 (2016), 615–626.

Jin

Gao

Flagg

and Deng

, Tobacco-specific nitrosamine 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone promotes functional cooperation of Bcl2 and c-Myc through phosphorylation in regulating cell survival and proliferation, J Biol Chem 279 (2004), 40209–40219.

Khan

A.A.

Advani

Patel

Nanjappa

Datta

K.K.

Solanki

H.S.

Kumar

Mathur

P.P.

Nair

Keshava Prasad

T.S.

Chatterjee

and Gowda

, Chronic exposure to cigarette smoke and chewing tobacco alters expression of microRNAs in esophageal epithelial cells, Microrna 7 (2018), 28–37.

Zhang

Dingle

R.W.

Gairola

C.G.

Valentino

and Swanson

H.I.

, Cigarette smoke condensate and dioxin suppress culture shock induced senescence in normal human oral keratinocytes, Oral Oncol 43 (2007), 693–700.

Sreeramareddy

C.T.

Pradhan

P.M.

Mir

I.A.

and Sin

, Smoking and smokeless tobacco use in nine South and Southeast Asian countries: prevalence estimates and social determinants from Demographic and Health Surveys, Popul Health Metr 12 (2014), 22.

Lee

C.H.

Lee

K.W.

Fang

F.M.

D.C.

Tsai

S.M.

Chen

P.H.

Shieh

T.Y.

Chen

C.H.

I.C.

Huang

H.L.

Chen

B.H.

Chang

C.H.

Chen

M.K.

Chou

S.H.

Tsai

Y.S.

Chiang

S.L.

and Ko

Y.C.

, The neoplastic impact of tobacco-free betel-quid on the histological type and the anatomical site of aerodigestive tract cancers, Int J Cancer 131 (2012), E733–743.

Gupta

and Johnson

N.W.

, Systematic review and meta-analysis of association of smokeless tobacco and of betel quid without tobacco with incidence of oral cancer in South Asia and the Pacific, PLoS One 9 (2014), e113385.

Abdulla

Adyanthaya

Kini

Mohanty

D’Souza

and Subbannayya

, Clinicopathological analysis of oral squamous cell carcinoma among the younger age group in coastal Karnataka, India: a retrospective study, J Oral Maxillofac Pathol 22 (2018), 180–187.

10.

Hirayama

, An epidemiological study of oral and pharyngeal cancer in Central and South-East Asia, Bull World Health Organ 34 (1966), 41–69.

11.

Gupta

P.C.

Pednekar

M.S.

Parkin

D.M.

and Sankaranarayanan

, Tobacco associated mortality in Mumbai (Bombay) India. Results of the Bombay Cohort Study, Int J Epidemiol 34 (2005), 1395–1402.

12.

Shpitzer

Hamzany

Bahar

Feinmesser

Savulescu

Borovoi

Gavish

and Nagler

R.M.

, Salivary analysis of oral cancer biomarkers, Br J Cancer 101 (2009), 1194–1198.

13.

Datta

K.K.

Patil

Patel

Babu

Raja

Nanjappa

Mangalaparthi

K.K.

Dhaka

Rajagopalan

Deolankar

S.C.

Kannan

Kumar

Prasad

T.S.K.

Mathur

P.P.

Kumari

Manoharan

Coral

Murugan

Sidransky

Gupta

Khanna-Gupta

Chatterjee

and Gowda

, Chronic exposure to chewing tobacco induces metabolic reprogramming and cancer stem cell-like properties in esophageal epithelial cells, Cells 8 (2019).

14.

Rajagopalan

Patel

Jain

A.P.

Nanjappa

Datta

K.K.

Subbannayya

Mangalaparthi

K.K.

Kumari

Manoharan

Coral

Murugan

Nair

Prasad

T.S.K.

Mathur

P.P.

Gupta

Khanna-Gupta

Califano

Sidransky

Gowda

and Chatterjee

, Molecular alterations associated with chronic exposure to cigarette smoke and chewing tobacco in normal oral keratinocytes, Cancer Biol Ther 19 (2018), 773–785.

15.

Boffetta

Hecht

Gray

Gupta

and Straif

, Smokeless tobacco and cancer, Lancet Oncol 9 (2008), 667–675.

16.

Sadri

and Mahjub

, Tobacco smoking and oral cancer: a meta-analysis, J Res Health Sci 7 (2007), 18–23.

17.

Hoffmann

and Adams

J.D.

, Carcinogenic tobacco-specific N-nitrosamines in snuff and in the saliva of snuff dippers, Cancer Res 41 (1981), 4305–4308.

18.

Humans

I.W.G.o.t.E.o.C.R.t.

, Tobacco smoke and involuntary smoking, IARC Monogr Eval Carcinog Risks Hum 83 (2004), 1–1438.

19.

Humans

I.W.G.o.t.E.o.C.R.t.

, Smokeless tobacco and some tobacco-specific N-nitrosamines, IARC Monogr Eval Carcinog Risks Hum 89 (2007), 1–592.

20.

Bijian

Mlynarek

A.M.

Balys

R.L.

Jie

Hier

M.P.

Black

M.J.

Di Falco

M.R.

LaBoissiere

and Alaoui-Jamali

M.A.

, Serum proteomic approach for the identification of serum biomarkers contributed by oral squamous cell carcinoma and host tissue microenvironment, J Proteome Res 8 (2009), 2173–2185.

21.

Gleber-Netto

F.O.

Yakob

Feng

Dai

Kao

H.K.

Chang

Y.L.

Chang

K.P.

and Wong

D.T.

, Salivary biomarkers for detection of oral squamous cell carcinoma in a taiwanese population, Clin Cancer Res 22 (2016), 3340–3347.

22.

Feng

Chen

Fan

Cui

Chen

Zhang

Jiang

Zhou

and Zhang

, Salivary protease spectrum biomarkers of oral cancer, Int J Oral Sci 11 (2019), 7.

23.

Fernandez-Olavarria

Mosquera-Perez

Diaz-Sanchez

R.M.

Serrera-Figallo

M.A.

Gutierrez-Perez

J.L.

and Torres-Lagares

, The role of serum biomarkers in the diagnosis and prognosis of oral cancer: a systematic review, J Clin Exp Dent 8 (2016), e184–193.

24.

Liu

Xie

Xue

Wei

Liang

and Chen

, Diagnostic accuracy and prognostic applications of CYFRA 21-1 in head and neck cancer: a systematic review and meta-analysis, PLoS One 14 (2019), e0216561.

25.

Thompson

Schafer

Kuhn

Kienle

Schwarz

Schmidt

Neumann

Johnstone

Mohammed

A.K.

and Hamon

, Tandem mass tags: a novel quantification strategy for comparative analysis of complex protein mixtures by MS/MS, Anal Chem 75 (2003), 1895–1904.

26.

Rappsilber

Mann

and Ishihama

, Protocol for micro-purification, enrichment, pre-fractionation and storage of peptides for proteomics using StageTips, Nat Protoc 2 (2007), 1896–1906.

27.

Kulak

N.A.

Pichler

Paron

Nagaraj

and Mann

, Minimal, encapsulated proteomic-sample processing applied to copy-number estimation in eukaryotic cells, Nat Methods 11 (2014), 319–324.

28.

Mohanty

Subbannayya

Najar

M.A.

Pinto

S.M.

Kasaragod

Karuppiah

Sreeramulu

Singh

K.K.

Dalal

Manikkoth

Arunachalam

Prasad

T.S.K.

and Murthy

K.R.

, Proteomics and visual health research: proteome of the human sclera using high-resolution mass spectrometry, OMICS 23 (2019), 98–110.

29.

Olsen

J.V.

de Godoy

L.M.

Macek

Mortensen

Pesch

Makarov

Lange

Horning

and Mann

, Parts per million mass accuracy on an Orbitrap mass spectrometer via lock mass injection into a C-trap, Mol Cell Proteomics 4 (2005), 2010–2021.

30.

Vizcaino

J.A.

Deutsch

E.W.

Wang

Csordas

Reisinger

Rios

Dianes

J.A.

Sun

Farrah

Bandeira

Binz

P.A.

Xenarios

Eisenacher

Mayer

Gatto

Campos

Chalkley

R.J.

Kraus

H.J.

Albar

J.P.

Martinez-Bartolome

Apweiler

Omenn

G.S.

Martens

Jones

A.R.

and Hermjakob

, ProteomeXchange provides globally coordinated proteomics data submission and dissemination, Nat Biotechnol 32 (2014), 223–226.

31.

Huang da

Sherman

B.T.

and Lempicki

R.A.

, Bioinformatics enrichment tools: paths toward the comprehensive functional analysis of large gene lists, Nucleic Acids Res 37 (2009), 1–13.

32.

Kumari

and Malla

, New insight on the role of plasminogen receptor in cancer progression, Cancer Growth Metastasis 8 (2015), 35–42.

33.

Nejedla

Sadi

Sulimenko

de Almeida

F.N.

Blom

Draber

Aspenstrom

and Karlsson

, Profilin connects actin assembly with microtubule dynamics, Mol Biol Cell 27 (2016), 2381–2393.

34.

Roman

Ritzenthaler

J.D.

Gil-Acosta

Rivera

H.N.

and Roser-Page

, Nicotine and fibronectin expression in lung fibroblasts: implications for tobacco-related lung tissue remodeling, FASEB J 18 (2004), 1436–1438.

35.

Zhang

Jin

Guo

Wang

Yang

Song

Cheng

Gong

and Sun

, Dramatically changed immune-related molecules as early diagnostic biomarkers of non-small cell lung cancer, FEBS J 287 (2020), 783–799.

36.

Rubio

C.A.

, Lysozyme is up-regulated in columnar-lined Barrett’s mucosa: a possible natural defence mechanism against Barrett’s esophagus-associated pathogenic bacteria, Anticancer Res 32 (2012), 5115–5119.

37.

Y.F.

and Huang

Y.R.

, Arylsulfatase, betagalactosidase and lysozyme in gastric cancer cells and its relationship to invasion, World J Gastroenterol 4 (1998), 52–54.

38.

Ren

Zheng

Liu

Wang

and Du

, Apolipoproteins and cancer, Cancer Med 8 (2019), 7032–7043.

39.

Malik

Ward

M.D.

Gupta

S.K.

Trosset

M.W.

Grizzle

W.E.

Adam

B.L.

Diaz

J.I.

and Semmes

O.J.

, Serum levels of an isoform of apolipoprotein A-II as a potential marker for prostate cancer, Clin Cancer Res 11 (2005), 1073–1085.

40.

Liu

Sogawa

Sunaga

Umemura

Satoh

Kazami

Yoshikawa

Tomonaga

Yokosuka

and Nomura

, Increased concentrations of apo A-I and apo A-II fragments in the serum of patients with hepatocellular carcinoma by magnetic beads-assisted MALDI-TOF mass spectrometry, Am J Clin Pathol 141 (2014), 52–61.

41.

Honda

Kobayashi

Okusaka

Rinaudo

J.A.

Huang

Marsh

Sanada

Sasajima

Nakamori

Shimahara

Ueno

Tsuchida

Sata

Ioka

Yasunami

Kosuge

Miura

Kamita

Sakamoto

Shoji

Jung

Srivastava

and Yamada

, Plasma biomarker for detection of early stage pancreatic cancer and risk factors for pancreatic malignancy using antibodies for apolipoprotein-AII isoforms, Sci Rep 5 (2015), 15921.

42.

Chu

H.W.

Chang

K.P.

Hsu

C.W.

Chang

I.Y.

Liu

H.P.

Chen

Y.T.

and Wu

C.C.

, Identification of salivary biomarkers for oral cancer detection with untargeted and targeted quantitative proteomics approaches, Mol Cell Proteomics 18 (2019), 1796–1806.

43.

Kjeldsen

Lauritsen

and De Muckadell

O.B.

, Serum concentrations of orosomucoid: improved decision-making for tapering prednisolone therapy in patients with active inflammatory bowel disease? Scand J Gastroenterol 32 (1997), 933–941.

44.

Irmak

Tilki

Heukeshoven

Oliveira-Ferrer

Friedrich

Huland

and Ergun

, Stage-dependent increase of orosomucoid and zinc-alpha2-glycoprotein in urinary bladder cancer, Proteomics 5 (2005), 4296–4304.

45.

Zhang

Xiao

Liu

Wang

Zheng

Dong

Zhuang

and Wang

, The potential role of ORM2 in the development of colorectal cancer, PLoS One 7 (2012), e31868.

46.

Oikonomopoulou

Ricklin

Ward

P.A.

and Lambris

J.D.

, Interactions between coagulation and complement-their role in inflammation, Semin Immunopathol 34 (2012), 151–165.

47.

Amara

Rittirsch

Flierl

Bruckner

Klos

Gebhard

Lambris

J.D.

and Huber-Lang

, Interaction between the coagulation and complement system, Adv Exp Med Biol 632 (2008), 71–79.

48.

Sun

Z.Q.

Han

X.N.

Wang

H.J.

Tang

Zhao

Z.L.

Y.L.

R.W.

Liu

Y.Y.

and Yu

X.B.

, Prognostic significance of preoperative fibrinogen in patients with colon cancer, World J Gastroenterol 20 (2014), 8583–8591.

49.

Ren

Bai

Wang

and Zhou

, Prognostic sig-nificance of pretreatment plasma fibrinogen in patients with hepatocellular and pancreatic carcinomas: a meta-analysis, Medicine (Baltimore) 97 (2018), e10824.

50.

S.S.

Wang

Yang

Chen

H.Y.

Liang

S.B.

L.X.

and Chen

, Plasma fibrinogen correlates with metastasis and is associated with prognosis in human nasopharyngeal carcinoma, J Cancer 8 (2017), 403–409.

51.

Gharat

Rathod

G.P.

and Kandalgaonkar

, Quantitative estimation of serum fibrinogen degradation product levels in oral premalignant and malignant lesions, J Int Oral Health 5 (2013), 65–72.

52.

Csosz

Markus

Darula

Medzihradszky

K.F.

Nemes

Szabo

Tozser

Kiss

and Marton

, Salivary proteome profiling of oral squamous cell carcinoma in a Hungarian population, FEBS Open Bio 8 (2018), 556–569.

53.

Savola

Klami

Myllykangas

Manara

Scotlandi

Picci

Knuutila

and Vakkila

, High expression of complement component 5 (C5) at tumor site associates with superior survival in ewing’s sarcoma family of tumour patients, ISRN Oncol 2011 (2011), 168712.

54.

Medler

T.R.

Murugan

Horton

Kumar

Cotechini

Forsyth

A.M.

Leyshock

Leitenberger

J.J.

Kulesz-Martin

Margolin

A.A.

Werb

and Coussens

L.M.

, Complement C5a fosters squamous carcinogenesis and limits T cell response to chemotherapy, Cancer Cell 34 (2018), 561–578 e6.

55.

Peltier

Roperch

J.P.

Audebert

Borg

J.P.

and Camoin

, Activation peptide of the coagulation factor XIII (AP-F13A1) as a new biomarker for the screening of colorectal cancer, Clin Proteomics 15 (2018), 15.

56.

Koontongkaew

, The tumor microenvironment contribution to development, growth, invasion and metastasis of head and neck squamous cell carcinomas, J Cancer 4 (2013), 66–83.

57.

Becerra

S.P.

and Notario

, The effects of PEDF on cancer biology: mechanisms of action and therapeutic potential, Nat Rev Cancer 13 (2013), 258–271.

58.

Liu

and Chang

, TXNDC5 is a cervical tumor susceptibility gene that stimulates cell migration, vasculogenic mimicry and angiogenesis by down-regulating SERPINF1 and TRAF1 expression, Oncotarget 8 (2017), 91009–91024.

59.

Martinez-Marin

Jarvis

Nelius

de Riese

Volpert

O.V.

and Filleur

, PEDF increases the tumoricidal activity of macrophages towards prostate cancer cells in vitro , PLoS One 12 (2017), e0174968.

60.

Kew

R.R.

Ghebrehiwet

and Janoff

, Cigarette smoke can activate the alternative pathway of complement in vitro by modifying the third component of complement, J Clin Invest 75 (1985), 1000–1007.

61.

Boue

De Leon

Schlage

W.K.

Peck

M.J.

Weiler

Berges

Vuillaume

Martin

Friedrichs

Lebrun

Meurrens

Schracke

Moehring

Steffen

Schueller

Vanscheeuwijck

Peitsch

M.C.

and Hoeng

, Cigarette smoke induces molecular responses in respiratory tissues of ApoE(-/-) mice that are progressively deactivated upon cessation, Toxicology 314 (2013), 112–124.

62.

Chang

Chowdhry

Budhu

and Kew

R.R.

, Smokeless tobacco extracts activate complement in vitro: a potential pathogenic mechanism for initiating inflammation of the oral mucosa, Clin Immunol Immunopathol 87 (1998), 223–229.

Molecular alterations in oral cancer between tobacco chewers and smokers using serum proteomics

Abstract

BACKGROUND:

OBJECTIVE:

METHODS:

RESULTS:

CONCLUSIONS

Keywords

Abbreviations

1. Introduction

2. Materials and methods

2.1 Study subject, sample collection, and storage

2.2 Sample preparation for MS analysis

2.3 In-solution digestion and TMT labeling

2.4 Mass spectrometry analysis

2.5 Bioinformatics and statistical analysis

2.6 Enzyme-linked immunosorbent assay (ELISA)

2.7 Data availability

3.1 Comparative proteomic analysis of serum from OSCC patients

Table 1 A list of top six differentially expressed proteins based on tobacco using habits of OSCC patients

4. Discussion

5. Conclusions

Author contributions

Supplementary data

sj-pdf-1-cbm-10.3233_CBM-203077.pdf - Supplemental material

sj-docx-1-cbm-10.3233_CBM-203077.docx - Supplemental material

Footnotes

Acknowledgments

Conflict of interest

References

Table 1
A list of top six differentially expressed proteins based on tobacco using habits of OSCC patients